Skip to main content

Kepler Capital Keeps Their Buy Rating on Novartis AG (NOVN)

Tipranks - Tipranks - Fri Feb 6, 7:46PM CST

Kepler Capital analyst David Evans maintained a Buy rating on Novartis AG on February 4 and set a price target of CHF106.00. The company’s shares closed yesterday at CHF118.70.

Claim 50% Off TipRanks Premium

Evans covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Novartis AG, and Merck KGaA. According to TipRanks, Evans has an average return of 2.5% and a 60.37% success rate on recommended stocks.

In addition to Kepler Capital , Novartis AG also received a Buy from Citi’s Graham Parry in a report issued yesterday. However, on the same day, Barclays maintained a Hold rating on Novartis AG (Six Swiss: NOVN).

See the top stocks recommended by analysts >>

Based on Novartis AG’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of CHF14.36 billion and a net profit of CHF3.93 billion. In comparison, last year the company earned a revenue of CHF13.17 billion and had a net profit of CHF3.19 billion

Read More on CH:NOVN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).